What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:
Roth Capital Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $40
Roth Capital analyst Elemer Piros downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Buy to Neutral and lowers the price target from $46 to $40.
Apellis Pharma Reiterates Plan To Submit New Drug Application In H1’22 For Pegcetacoplan For Geographic Atrophy Following FDA Feedback
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that it received formal, written feedback from the U.S. Food and Drug Administration (FDA) that further reinforces the company’s plans to submit a New
Where Apellis Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter:
Apellis Pharmaceuticals Q3 EPS $(2.28) Misses $(1.75) Estimate, Sales $5.70M Miss $7.22M Estimate
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(1.75) by 30.29 percent. This is a 27.37 percent decrease over losses of $(1.79) per
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Apellis Pharma Reports Positive CHMP Opinion For Aspaveli For Treatment Of Paroxysmal Nocturnal Hemoglobinuria
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
Cramer Likes DraftKings, Skyworks, And These Automakers
On CNBC's "Mad Money Lightning Round," Jim Cramer said he was a buyer of DraftKings Inc (NASDAQ: DKNG).
Apellis Pharmaceuticals Announces Detailed Results From Phase 3 DERBY And OAKS Studies Presented At Retina Society Annual Meeting
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that detailed data from the Phase 3 DERBY and OAKS studies were presented for the first time as